TY - JOUR
T1 - Behavioral Weight Loss Intervention for Migraine
T2 - A Randomized Controlled Trial
AU - Bond, Dale S.
AU - Thomas, J. Graham
AU - Lipton, Richard B.
AU - Roth, Julie
AU - Pavlovic, Jelena M.
AU - Rathier, Lucille
AU - O'Leary, Kevin C.
AU - Evans, E. Whitney
AU - Wing, Rena R.
N1 - Funding Information:
Funding agencies: This work was supported by the National Institutes of Health (R01 NS077925; Primary Investigator: DSB). Disclosure: DSB receives research support from the Norman Prince Neurosciences Institute and previously received partial funding through grants from Weight Watchers International, Inc. He has previously received travel/conference registration support from The American Headache Society. JGT previously received partial funding through grants from NIH (R01 NS077925) and Weight Watchers International, Inc. RBL receives research support from the NIH: 2P01 AG003949 (Program Director), 5U10 NS077308 (Primary Investigator), 1R01 AG042595 (Investigator), R01 NS082432 (Investigator), K23 NS09610 (Mentor), and K23AG049466 (Mentor). He also receives support from the Migraine Research Foundation and the National Headache Foundation. He serves on the editorial board of Neurology and as senior advisor to Headache. He holds stock options in eNeura Therapeutics and Biohaven Holdings and serves as consultant and advisory board member or has received honoraria from the American Academy of Neurology, Alder, Allergan, the American Headache Society, Amgen, Autonomic Technologies, Avanir, Biohaven, Biovision, Boston Scientific, Colucid, Dr Reddy’s, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKlein, Merck, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, and Vedanta. He receives royalties from Wolff’s Headache and Other Head Pain (8th edition, Oxford Press University, 2009), Wiley, and Informa. JMP received consulting honoraria and travel support from Allergan, Inc. and travel/conference registration support from The American Headache Society. The other authors declared no conflict of interest. Author contributions: Conception and design: DSB, JGT, RBL, JR, JMP, LR, and RRW. Acquisition of data: DSB, JGT, JR, KCO, EWE, and RRW. Statistical analysis: JGT. Drafting the manuscript: DSB and JGT. All authors contributed to data interpretation, revising the manuscript for intellectual content, and final approval of the completed manuscript. Clinical trial registration: ClinicalTrials.gov identifier NCT01197196. Received: 25 September 2017; Accepted: 19 October 2017; Published online 27 November 2017. doi:10.1002/oby.22069
PY - 2018/1
Y1 - 2018/1
N2 - Objective: The objective of this study was to test whether behavioral weight loss (BWL) intervention decreases headaches in women with comorbid migraine and overweight or obesity. Methods: This randomized, single-blind trial allocated women 18 to 50 years old with 4 to 20 migraine days per month and a BMI = 25.0-49.9 kg/m2 to 16 weeks of BWL (n = 54), which targeted exercise and eating behaviors for weight loss, or to migraine education control (ME, n = 56), which delivered didactic instruction on migraine and treatments. Participants completed a 4-week smartphone headache diary at baseline, posttreatment (16-20 wk), and follow-up (32-36 wk). The primary outcome was posttreatment change in migraine days per month, analyzed via linear mixed effects models. Results: Of 110 participants randomly assigned, 85 (78%) and 80 (73%) completed posttreatment and follow-up. Although the BWL group achieved greater weight loss (mean [95% CI] in kilograms) than the ME group at posttreatment (−3.8 [−2.5 to −5.0] vs. + 0.9 [−0.4 to 2.2], P < 0.001) and follow-up (−3.2 [−2.0 to −4.5] vs. + 1.1 [−0.2 to 2.4], P < 0.001), there were no significant group (BWL vs. ME) differences (mean [95% CI]) in migraine days per month at posttreatment (−3.0 [−2.0 to −4.0] vs. −4.0 [−2.9 to −5.0], P = 0.185) or follow-up (−3.8 [−2.7 to −4.8] vs. −4.4 [−3.4 to −5.5], P = 0.378). Conclusions: Contrary to hypotheses, BWL and ME yielded similar, sustained reductions in migraine headaches. Future research should evaluate whether adding BWL to standard pharmacological and/or nonpharmacological migraine treatment approaches yields greater benefits.
AB - Objective: The objective of this study was to test whether behavioral weight loss (BWL) intervention decreases headaches in women with comorbid migraine and overweight or obesity. Methods: This randomized, single-blind trial allocated women 18 to 50 years old with 4 to 20 migraine days per month and a BMI = 25.0-49.9 kg/m2 to 16 weeks of BWL (n = 54), which targeted exercise and eating behaviors for weight loss, or to migraine education control (ME, n = 56), which delivered didactic instruction on migraine and treatments. Participants completed a 4-week smartphone headache diary at baseline, posttreatment (16-20 wk), and follow-up (32-36 wk). The primary outcome was posttreatment change in migraine days per month, analyzed via linear mixed effects models. Results: Of 110 participants randomly assigned, 85 (78%) and 80 (73%) completed posttreatment and follow-up. Although the BWL group achieved greater weight loss (mean [95% CI] in kilograms) than the ME group at posttreatment (−3.8 [−2.5 to −5.0] vs. + 0.9 [−0.4 to 2.2], P < 0.001) and follow-up (−3.2 [−2.0 to −4.5] vs. + 1.1 [−0.2 to 2.4], P < 0.001), there were no significant group (BWL vs. ME) differences (mean [95% CI]) in migraine days per month at posttreatment (−3.0 [−2.0 to −4.0] vs. −4.0 [−2.9 to −5.0], P = 0.185) or follow-up (−3.8 [−2.7 to −4.8] vs. −4.4 [−3.4 to −5.5], P = 0.378). Conclusions: Contrary to hypotheses, BWL and ME yielded similar, sustained reductions in migraine headaches. Future research should evaluate whether adding BWL to standard pharmacological and/or nonpharmacological migraine treatment approaches yields greater benefits.
UR - http://www.scopus.com/inward/record.url?scp=85038404443&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85038404443&partnerID=8YFLogxK
U2 - 10.1002/oby.22069
DO - 10.1002/oby.22069
M3 - Article
C2 - 29178659
AN - SCOPUS:85038404443
VL - 26
SP - 81
EP - 87
JO - Obesity
JF - Obesity
SN - 1930-7381
IS - 1
ER -